BiotechTube
BrainEver

BrainEver

Paris, France· Est.
brainever.fr
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $2.5M

Overview

BrainEver is a clinical-stage biotech pioneering a novel therapeutic class based on homeoproteins—neuron maintenance and rejuvenation factors—to treat neurodegenerative diseases. The company's lead program, BREN02 (hEN1 for ALS), is in late preclinical development, supported by a recent €33M Series B financing to initiate a European clinical trial. With a pipeline spanning ALS, Parkinson's, and retinal disorders, BrainEver aims to deliver disease-modifying treatments by targeting the underlying biology of neuronal survival and function.

Neurodegenerative DiseasesOphthalmology

Technology Platform

Therapeutic application of homeoproteins (hEN1, hOTX2) as neuron maintenance and rejuvenation factors, delivered via recombinant protein or AAV-based gene therapy.

Funding History

1
Total raised:$2.5M
Seed$2.5M

Opportunities

The company is targeting large, underserved markets in neurodegeneration (ALS, PD) and ophthalmology (Glaucoma, AMD) with a first-in-class platform.
A successful clinical proof-of-concept in ALS could validate the entire homeoprotein approach, creating significant value and partnership potential across its broader pipeline.

Risk Factors

Primary risks include the high clinical uncertainty of a novel therapeutic class, significant delivery challenges for CNS targets, and intense competition in neurodegenerative diseases.
The company is also dependent on future financing to advance beyond its Series B-funded milestones.

Competitive Landscape

BrainEver faces competition from numerous biopharma companies developing neuroprotective agents, gene therapies, and other modalities for ALS and PD. Its differentiation lies in the unique homeoprotein mechanism targeting neuronal maintenance. In ophthalmology, it would compete with established players but offers a novel neuroprotective approach distinct from current standards of care.

More companies in Biologics / Biosimilars →More companies in France →